Accessible text: pCPA Dashboard

Accessible text for the pCPA June 2024 Dashboard

Data effective: May 31, 2024

For questions regarding this report, please contact: [email protected]

Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA’s inception, 591 negotiations have reached a letter of intent (LOI), including:

• 211 for oncology
• 58 for biosimilars 
• 69 for expensive drugs for rare diseases (EDRD)

Data for stacked line graph: Letters of intent

Month	Biosimilar	EDRD	Other non-oncology	Other oncology
Aug 2012	0	0	2	0
Sep 2012	0	0	2	1
Oct 2012	0	0	3	1
Nov 2012	0	0	3	1
Dec 2012	0	0	3	1
Jan 2013	0	0	3	1
Feb 2013	0	0	3	1
Mar 2013	0	0	3	1
Apr 2013	0	0	4	1
May 2013	0	0	5	2
Jun 2013	0	0	6	2
Jul 2013	0	0	6	2
Aug 2013	0	0	8	3
Sep 2013	0	0	9	5
Oct 2013	0	2	9	7
Nov 2013	0	2	10	9
Dec 2013	0	2	11	10
Jan 2014	0	2	11	11
Feb 2014	0	2	11	14
Mar 2014	0	2	12	15
Apr 2014	0	2	12	16
May 2014	0	2	14	17
Jun 2014	0	2	14	17
Jul 2014	0	3	14	19
Aug 2014	0	3	16	21
Sep 2014	0	4	17	22
Oct 2014	0	4	19	22
Nov 2014	0	5	20	22
Dec 2014	0	5	20	22
Jan 2015	0	5	20	22
Feb 2015	0	5	23	23
Mar 2015	0	5	28	23
Apr 2015	0	5	31	25
May 2015	0	5	36	25
Jun 2015	0	5	38	26
Jul 2015	0	5	40	27
Aug 2015	0	5	42	28
Sep 2015	0	5	44	28
Oct 2015	0	5	46	29
Nov 2015	0	5	46	30
Dec 2015	1	5	46	32
Jan 2016	1	5	49	32
Feb 2016	1	5	50	32
Mar 2016	1	5	52	33
Apr 2016	1	6	55	33
May 2016	1	6	59	33
Jun 2016	1	6	60	34
Jul 2016	1	6	61	35
Aug 2016	1	6	62	36
Sep 2016	1	7	64	36
Oct 2016	1	9	65	38
Nov 2016	2	10	66	39
Dec 2016	2	10	67	39
Jan 2017	3	10	68	39
Feb 2017	3	10	68	43
Mar 2017	3	10	75	43
Apr 2017	3	10	80	43
May 2017	3	10	81	43
Jun 2017	3	11	81	46
Jul 2017	4	11	83	50
Aug 2017	5	11	84	51
Sep 2017	5	11	84	54
Oct 2017	5	11	84	55
Nov 2017	6	12	86	55
Dec 2017	6	13	88	60
Jan 2018	6	14	92	63
Feb 2018	6	15	93	64
Mar 2018	6	15	97	64
Apr 2018	6	15	98	65
May 2018	6	16	99	65
Jun 2018	6	17	99	66
Jul 2018	6	18	100	67
Aug 2018	7	19	104	70
Sep 2018	7	22	109	70
Oct 2018	7	23	112	70
Nov 2018	7	23	114	70
Dec 2018	7	26	117	73
Jan 2019	7	26	122	75
Feb 2019	7	26	122	78
Mar 2019	8	26	128	79
Apr 2019	8	26	129	84
May 2019	8	26	131	85
Jun 2019	8	26	133	85
Jul 2019	8	27	136	85
Aug 2019	9	28	139	86
Sep 2019	10	28	141	90
Oct 2019	11	28	144	92
Nov 2019	13	28	146	94
Dec 2019	14	28	154	97
Jan 2020	14	28	155	97
Feb 2020	14	29	155	98
Mar 2020	15	31	156	100
Apr 2020	15	31	158	101
May 2020	16	33	160	107
Jun 2020	16	33	160	107
Jul 2020	19	34	160	108
Aug 2020	20	34	163	111
Sep 2020	20	34	163	112
Oct 2020	21	34	163	113
Nov 2020	21	36	164	115
Dec 2020	22	37	165	117
Jan 2021	22	37	176	118
Feb 2021	27	37	178	119
Mar 2021	27	38	182	121
Apr 2021	28	38	182	122
May 2021	30	38	182	124
Jun 2021	31	38	183	125
Jul 2021	31	40	184	125
Aug 2021	31	40	185	127
Sep 2021	33	40	189	132
Oct 2021	34	42	193	132
Nov 2021	36	43	194	136
Dec 2021	36	43	197	137
Jan 2022	36	43	199	141
Feb 2022	37	44	199	144
Mar 2022	38	45	200	150
Apr 2022	41	46	204	151
May 2022	41	46	206	152
Jun 2022	46	46	206	155
Jul 2022	46	47	207	156
Aug 2022	46	48	207	158
Sep 2022	46	49	213	161
Oct 2022	46	51	215	162
Nov 2022	46	54	215	165
Dec 2022	48	55	217	168
Jan 2023	48	55	218	171
Feb 2023	49	56	221	171
Mar 2023	49	57	221	171
Apr 2023	51	58	223	184
May 2023	51	60	227	184
Jun 2023	52	60	228	195
Jul 2023	52	61	230	197
Aug 2023	53	62	231	199
Sep 2023	54	62	233	200
Oct 2023	54	62	236	201
Nov 2023	56	65	237	204
Dec 2023	56	65	239	206
Jan 2024	56	66	242	207
Feb 2024	57	68	245	207
Mar 2024	58	68	246	210
Apr 2024	58	68	247	211
May 2024	58	69	253	211

Savings

Lower drug costs

As of April 1, 2024 savings from pCPA activities to participating drug plans are estimated to be $4.63B annually.

• $3.72B from brand name drugs
• $914M from generic drugs 
• Cumulative savings are estimated to be $24.1B

Data for stacked bar chart: Savings

Fiscal Year	Brand name drugs	Generic drug negotiations	Total
FY 16/17	$947,007,363	$355,000,000	$1,302,007,363
FY 17/18	$1,263,644,399	$740,000,000	$2,003,644,399
FY 18/19	$1,539,331,475	$740,000,000	$2,279,331,475
FY 19/20	$1,847,496,049	$740,000,000	$2,587,496,049
FY 20/21	$2,185,315,806	$740,000,000	$2,925,315,806
FY 21/22	$2,667,069,216	$750,000,000	$3,417,069,216
FY 22/23	$3,142,207,211	$750,000,000	$3,892,207,211
FY 23/24	$3,715,798,849	$913,979,661	$4,629,778,510

HTA and pCPA volumes

• The volume of recommendations has remained stable over time
• The pCPA has increased its capacity to conduct negotiations since its inception, notwithstanding the impacts of the COVID-19 pandemic

Data for bar charts: HTA and PCPA volumes

Three bar charts tracking number of CDA recommendations issued, pCPA files engaged, and pCPA files closed, with 2024 projections shown as a stacked bar.

Year	CDA recommendations issued	pCPA files engaged	pCPA files closed
2015	65	43	41
2016	64	51	38
2017	47	61	68
2018	62	73	64
2019	63	75	82
2020	57	70	68
2021	65	85	74
2022	82	83	90
2023	59	81	93
2024	37	30	29
End of year projected	52	42	41

pCPA activity

• There was growth in files in consideration over time, yet significant improvements were made with very few files in consideration during 2019 
• The COVID-19 pandemic impacted pCPA capacity, leading to more files in consideration from 2020 to 2023
• pCPA capacity to lead files has grown over time, with an increase in active negotiations up to 2019
• There was a brief reduction in active files in early 2020, followed by an increase in 2021 to 2023 approaching prior levels

Data for line graphs: pcPA activity 

Two line graphs:

• Files under consideration: HTA recommendation to pCPA engagement
• Active negotiations: pCPA engagement to LOI

Month	Files under consideration (average)	Active Negotiations (average)
Apr 2016	19	22.25
May 2016	19.6	23.2
Jun 2016	19.5	25.75
Jul 2016	16.8	31
Aug 2016	19	34.5
Sep 2016	21.75	38
Oct 2016	23.2	33.8
Nov 2016	25.25	38.5
Dec 2016	27	41.75
Jan 2017	25.8	41.6
Feb 2017	23	38
Mar 2017	22.75	31.75
Apr 2017	25.2	32.2
May 2017	23	41
Jun 2017	22.75	43
Jul 2017	20.8	42.4
Aug 2017	18	48
Sep 2017	14.25	47.75
Oct 2017	13.8	49.6
Nov 2017	15.5	45.5
Dec 2017	18.8	40
Jan 2018	18.5	35
Feb 2018	22.5	35.75
Mar 2018	23.5	37.5
Apr 2018	25.2	40.4
May 2018	27.25	45.25
Jun 2018	28.5	43.5
Jul 2018	28.4	45.4
Aug 2018	23.5	47.25
Sep 2018	22.2	49.4
Oct 2018	16	53.25
Nov 2018	16.25	54.25
Dec 2018	13.2	49
Jan 2019	13	44.75
Feb 2019	14.75	42.75
Mar 2019	12.2	41.6
Apr 2019	10.5	43.75
May 2019	10	44
Jun 2019	13.2	46.4
Jul 2019	10.25	48.5
Aug 2019	9.25	47.25
Sep 2019	8.6	46.6
Oct 2019	5.25	45.25
Nov 2019	5.75	41
Dec 2019	9	34.2
Jan 2020	10	31.75
Feb 2020	10.5	31.75
Mar 2020	11.6	32
Apr 2020	15.25	27.5
May 2020	20.8	20.8
Jun 2020	23.75	26.5
Jul 2020	21.5	42.25
Aug 2020	23.2	44.6
Sep 2020	24	44.5
Oct 2020	23.75	44.25
Nov 2020	22.4	45.4
Dec 2020	25.5	42
Jan 2021	28.4	33
Feb 2021	27	32.75
Mar 2021	25.25	34.75
Apr 2021	26.25	33.25
May 2021	29.2	33
Jun 2021	28.25	34.75
Jul 2021	28.5	43
Aug 2021	29.4	44.2
Sep 2021	34	39.25
Oct 2021	35.2	35.8
Nov 2021	28	41.25
Dec 2021	23	45.75
Jan 2022	25	43
Feb 2022	28.25	42.75
Mar 2022	31.5	43.5
Apr 2022	32.25	43.5
May 2022	31.8	41.8
Jun 2022	30	35
Jul 2022	29.2	34.8
Aug 2022	30.5	36
Sep 2022	34	32.5
Oct 2022	38.2	30.8
Nov 2022	36.25	34.25
Dec 2022	38	33.75
Jan 2023	35.4	35.4
Feb 2023	37.25	37.5
Mar 2023	35.75	41.75
Apr 2023	33.4	35.6
May 2023	30	33
Jun 2023	27	33.25
Jul 2023	26	31.4
Aug 2023	25.5	26.25
Sep 2023	24	28.25
Oct 2023	23.6	27.8
Nov 2023	24.25	24
Dec 2023	25.8	24
Jan 2024	24.75	23.25
Feb 2024	25.5	21.75
Mar 2024	26.4	26.2
Apr 2024	27.75	31.75
May 2024	30.5	29.25

pCPA timelines

• Negotiation timelines improved with the introduction of the brand process guidelines in 2018 but were impacted by the COVID-19 pandemic
• Targeted negotiations process (TNP) improved active negotiation timelines
• A minority of files meet targets outlined in the brand process guidelines

Data for combination chart: Time under consideration* 

pCPA initiation year	Median months to pCPA milestones	Files meeting brand process guideline target (%)
2016	3.34	36.0%
2017	4.37	25.0%
2018	3.75	22.6%
2019	1.84	57.1%
2020	5.06	22.0%
2021	3.81	20.3%
2022	4.41	19.2%
2023	3.88	26.4%

Data for combination chart: Active negotiation time 

pCPA initiation year	Median months to pCPA milestones	Files meeting brand process guideline target (%)
2016	8.22	19.7%
2017	6.44	25.0%
2018	5.18	34.8%
2019	5.69	20.0%
2020	5.49	29.5%
2021	4.31	42.0%
2022	3.45	52.7%
2023	3.88	48.9%

Data for combination chart:  Total time* 

pCPA initiation year	Median months to pCPA milestones	Files meeting brand process guideline target (%)
2016	11.84	11.3%
2017	12.05	12.5%
2018	9.21	17.0%
2019	8.02	34.7%
2020	10.93	14.0%
2021	9.83	22.0%
2022	9.67	21.9%
2023	9.07	24.5%

* Time under consideration and total timelines are only assessed for files arising from HTA recommendations, and excludes files which do not undergo negotiations. pCPA targets outlined in the brand process guidelines are approximately two months for file engagement, four months for active negotiations and six months combined.